自動細胞計数装置の市場規模、シェア、動向分析レポート:製品別(装置、消耗品、付属品)、用途別(血液分析、幹細胞研究)、最終用途別、地域別、セグメント別予測、2024年~2030年Automated Cell Counting Market Size, Share & Trends Analysis Report By Product (Instruments, Consumables & Accessories), By Application (Blood Analysis, Stem Cell Research), By End-use, By Region, And Segment Forecasts, 2024 - 2030 自動細胞計数市場の成長と動向 Grand View Research, Inc.の最新レポートによると、世界の自動細胞計数市場規模は2030年までに89億3000万米ドルに達し、2024年から2030年までのCAGRは12.45%を記録すると予測... もっと見る
1~3営業日
サマリー自動細胞計数市場の成長と動向Grand View Research, Inc.の最新レポートによると、世界の自動細胞計数市場規模は2030年までに89億3000万米ドルに達し、2024年から2030年までのCAGRは12.45%を記録すると予測されている。慢性疾患や感染症の予防と治療における生物製剤のニーズの高まり、バイオテクノロジー&バイオ医薬品産業への投資の増加、高度な細胞ベースの研究開発が市場拡大の要因の一部である。生物製剤の開発では、生物製剤中の細胞濃度を管理するために、画像ベースのカウンターやフローサイトメーターなど、さまざまな細胞計数装置の使用が必要となるため、市場の成長見通しを後押ししている。 COVID-19パンデミックは、細胞計数装置や消耗品の利用に多大な影響を与えた。パンデミックでは、骨減少症やリンパ球減少症がCOVID-19の指標となる可能性があったため、細胞計数機器の使用が増加した。例えば、2021年6月、学術誌『BMC Infectious Diseases』に掲載された研究では、入院時の白血球数の多さがCOVID-19患者の死亡と大きく関連していることが発見された。その結果、COVID-19を治療する際には、より多くの白血球数が考慮されるようになった。このような進展により、COVID-19の流行は市場の成長に大きな影響を与えた。 HIV、麻疹、ジフテリアなどの対象疾患、がんやその他の血液疾患などの慢性疾患の発生率の増加、高スループットフローサイトメトリーや自動血液分析装置の利用率の増加が市場拡大の主な要因である。UNAIDSのデータによると、2022年には全世界で推定3,840万人がHIVに感染し、2021年には推定150万人が新たにHIVに感染した。その結果、感染症患者の増加が細胞計数機器と消耗品の需要を押し上げる可能性が高い。 例えば、Mindrayは2022年3月に新しいBC-700シリーズを発表した。BC-700シリーズは、赤血球沈降速度(ESR)測定とともに全血球算定(CBC)を含む革新的な血液学分析装置シリーズである。こうして市場の成長を後押ししている。 同市場は、幹細胞、癌、免疫学研究のための政府や民間投資の増加から恩恵を受けている。自動計数技術は、表現型同定、細胞ソーティング、単細胞分析などの用途で、細胞生物学やゲノミクス研究を推進する助成金プログラムに使用されている。例えば、米国国立衛生研究所(NIH)は、2021年に410億ドル以上の医療研究資金を全米の大学や研究所に交付したが、そのうちのかなりの割合が細胞ベースの研究プログラムに割り当てられた。このように、このような資金と資金が利用可能であるため、研究室はハイエンドの自動細胞分析ツールを入手することができ、市場の成長をさらに後押しする。 自動細胞計数市場レポートハイライト - 製品別では、消耗品とアクセサリーの分野が予測期間中に最も速いCAGRを示すと予測されている。自動細胞計数器用消耗品および付属品の度重なる調達により市場は拡大している - アプリケーション別では、幹細胞研究分野が予測期間中に最も速い成長が見込まれる。医療関係者や研究者による幹細胞研究や医薬品開発の増加が、世界市場の成長を促進すると予想される。 - 最終用途別では、病院・診断検査分野が予測期間中に最も急成長する見込みである。慢性疾患の有病率の増加、老人人口の増加、その他 - 北米は2023年に最大の収益シェアを占めた。これは、主要な市場参加者が存在すること、米国などにおける医療費の上昇がこの地域の市場を押し上げていることが主な要因である。 目次Table of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation and Scope 1.2. Market Definitions 1.2.1. Product Segment 1.2.2. Application Segment 1.2.3. End-user Segment 1.3. Information analysis 1.4. Market formulation & data visualization 1.5. Data validation & publishing 1.6. Information Procurement 1.6.1. Primary Research 1.7. Information or Data Analysis 1.8. Market Formulation & Validation 1.9. Market Model 1.10. Objectives 1.10.1. Objective 1 1.10.2. Objective 2 Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Snapshot 2.3. Competitive Landscape Snapshot Chapter 3. Market Variables, Trends, & Scope 3.1. Market Lineage Outlook 3.1.1. Parent Market Outlook 3.1.2. Related/Ancillary Market Outlook 3.2. Market Trends and Outlook 3.3. Market Dynamics 3.3.1. Increasing prevalence of chronic diseases 3.3.2. Technological advancements in cell counting instruments 3.3.3. Increasing government funding for cell-based research 3.4. Market Restraint Analysis 3.4.1. High costs of advanced cell counting systems 3.4.2. Low adoption in underdeveloped regions 3.5. Business Environment Analysis 3.5.1. PESTEL Analysis 3.5.2. Porter’s Five Forces Analysis 3.5.3. COVID-19 Impact Analysis Chapter 4. Product Business Analysis 4.1. Global Automated Cell Counting Market: Product Movement Analysis 4.2. Instruments 4.2.1. Instruments Market, 2018 - 2030 (USD Million) 4.2.2. Flow Cytometers 4.2.2.1. Flow Cytometers Market, 2018 - 2030 (USD Million) 4.2.3. Image-based Cell Counters 4.2.3.1. Image-based Cell Counters Market, 2018 - 2030 (USD Million) 4.2.4. Electrical Impendence Coulter Counters 4.2.4.1. Electrical Impendence Coulter Counters Market, 2018 - 2030 (USD Million) 4.3. Consumables & Accessories 4.3.1. Consumables & Accessories Market, 2018 - 2030 (USD Million) Chapter 5. Application Business Analysis 5.1. Global Automated Cell Counting Market: Application Movement Analysis 5.2. Blood Analysis 5.2.1. Blood Analysis Market, 2018 - 2030 (USD Million) 5.3. Stem Cell Research 5.3.1. Stem Cell Research Market, 2018 - 2030 (USD Million) 5.4. Cell Line development 5.4.1. Cell Line development Market, 2018 - 2030 (USD Million) 5.4.2. Biologics Production 5.4.2.1. Biologics Production Market, 2018 - 2030 (USD Million) 5.4.3. Cell & Gene Therapy 5.4.3.1. Cell & Gene Therapy Market, 2018 - 2030 (USD Million) 5.5. Others 5.5.1. Others Market, 2018 - 2030 (USD Million) Chapter 6. End-Use Business Analysis 6.1. Global Automated Cell Counting Market: End-use Movement Analysis 6.2. Pharmaceutical & Biotechnology Companies 6.2.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million) 6.3. Hospitals & Diagnostic laboratories 6.3.1. Hospitals & Diagnostic laboratories Market, 2018 - 2030 (USD Million) 6.4. Research & Academic Institutes 6.4.1. Research & Academic Institutes Market, 2018 - 2030 (USD Million) 6.5. Others 6.5.1. Others Market, 2018 - 2030 (USD Million) Chapter 7. Regional Business Analysis 7.1. Global Automated Cell Counting Market Share By Region, 2023 & 2030 7.2. North America 7.2.1. North America Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.2.2. U.S. 7.2.2.1. Key Country Dynamics 7.2.2.2. Competitive Scenario 7.2.2.3. Target Disease Prevalence 7.2.2.4. U.S. Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.2.3. Canada 7.2.3.1. Key Country Dynamics 7.2.3.2. Competitive Scenario 7.2.3.3. Target Disease Prevalence 7.2.3.4. Canada Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3. Europe 7.3.1. Europe Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3.2. Germany 7.3.2.1. Key Country Dynamics 7.3.2.2. Competitive Scenario 7.3.2.3. Target Disease Prevalence 7.3.2.4. Germany Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3.3. UK 7.3.3.1. Key Country Dynamics 7.3.3.2. Competitive Scenario 7.3.3.3. Target Disease Prevalence 7.3.3.4. UK Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3.4. France 7.3.4.1. Key Country Dynamics 7.3.4.2. Competitive Scenario 7.3.4.3. Target Disease Prevalence 7.3.4.4. France Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3.5. Italy 7.3.5.1. Key Country Dynamics 7.3.5.2. Competitive Scenario 7.3.5.3. Target Disease Prevalence 7.3.5.4. Italy Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3.6. Spain 7.3.6.1. Key Country Dynamics 7.3.6.2. Competitive Scenario 7.3.6.3. Target Disease Prevalence 7.3.6.4. Spain Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3.7. Denmark 7.3.7.1. Key Country Dynamics 7.3.7.2. Competitive Scenario 7.3.7.3. Target Disease Prevalence 7.3.7.4. Denmark Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3.8. Sweden 7.3.8.1. Key Country Dynamics 7.3.8.2. Competitive Scenario 7.3.8.3. Target Disease Prevalence 7.3.8.4. Sweden Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3.9. Norway 7.3.9.1. Key Country Dynamics 7.3.9.2. Competitive Scenario 7.3.9.3. Target Disease Prevalence 7.3.9.4. Norway Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.4. Asia Pacific 7.4.1. Asia Pacific Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.4.2. Japan 7.4.2.1. Key Country Dynamics 7.4.2.2. Competitive Scenario 7.4.2.3. Target Disease Prevalence 7.4.2.4. Japan Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.4.3. China 7.4.3.1. Key Country Dynamics 7.4.3.2. Competitive Scenario 7.4.3.3. Target Disease Prevalence 7.4.3.4. China Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.4.4. India 7.4.4.1. Key Country Dynamics 7.4.4.2. Competitive Scenario 7.4.4.3. Target Disease Prevalence 7.4.4.4. India Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.4.5. South Korea 7.4.5.1. Key Country Dynamics 7.4.5.2. Competitive Scenario 7.4.5.3. Target Disease Prevalence 7.4.5.4. South Korea Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.4.6. Australia 7.4.6.1. Key Country Dynamics 7.4.6.2. Competitive Scenario 7.4.6.3. Target Disease Prevalence 7.4.6.4. Australia Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.4.7. Thailand 7.4.7.1. Key Country Dynamics 7.4.7.2. Competitive Scenario 7.4.7.3. Target Disease Prevalence 7.4.7.4. Thailand Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.5. Latin America 7.5.1. Latin America Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.5.2. Brazil 7.5.2.1. Key Country Dynamics 7.5.2.2. Competitive Scenario 7.5.2.3. Target Disease Prevalence 7.5.2.4. Brazil Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.5.3. Mexico 7.5.3.1. Key Country Dynamics 7.5.3.2. Competitive Scenario 7.5.3.3. Target Disease Prevalence 7.5.3.4. Mexico Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.5.4. Argentina 7.5.4.1. Key Country Dynamics 7.5.4.2. Competitive Scenario 7.5.4.3. Target Disease Prevalence 7.5.4.4. Argentina Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.6. MEA 7.6.1. MEA Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.6.2. South Africa 7.6.2.1. Key Country Dynamics 7.6.2.2. Competitive Scenario 7.6.2.3. Target Disease Prevalence 7.6.2.4. South Africa Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.6.3. Saudi Arabia 7.6.3.1. Key Country Dynamics 7.6.3.2. Competitive Scenario 7.6.3.3. Target Disease Prevalence 7.6.3.4. Saudi Arabia Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.6.4. UAE 7.6.4.1. Key Country Dynamics 7.6.4.2. Competitive Scenario 7.6.4.3. Target Disease Prevalence 7.6.4.4. UAE Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.6.5. Kuwait 7.6.5.1. Key Country Dynamics 7.6.5.2. Competitive Scenario 7.6.5.3. Target Disease Prevalence 7.6.5.4. Kuwait Automated Cell Counting Market, 2018 - 2030 (USD Million) Chapter 8. Competitive Landscape 8.1. Company Categorization 8.2. Strategy Mapping 8.3. Company Market/Position Share Analysis, 2023 8.4. Company Profiles/Listing 8.4.1. Thermo Fisher Scientific Inc. 8.4.1.1. Overview 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.1.3. Product Benchmarking 8.4.1.4. Strategic Initiatives 8.4.2. Countstar, Inc. 8.4.2.1. Overview 8.4.2.2. Product Benchmarking 8.4.2.3. Strategic Initiatives 8.4.3. Bio-Rad Laboratories, Inc. 8.4.3.1. Overview 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.3.3. Product Benchmarking 8.4.3.4. Strategic Initiatives 8.4.4. F. Hoffmann-La Roche Ltd 8.4.4.1. Overview 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.4.3. Product Benchmarking 8.4.4.4. Strategic Initiatives 8.4.5. Chemometec A/S 8.4.5.1. Overview 8.4.5.2. Product Benchmarking 8.4.5.3. Strategic Initiatives 8.4.6. Danaher 8.4.6.1. Overview 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.6.3. Product Benchmarking 8.4.6.4. Strategic Initiatives 8.4.7. Olympus Corporation 8.4.7.1. Overview 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.7.3. Product Benchmarking 8.4.7.4. Strategic Initiatives 8.4.8. Merck KGaA 8.4.8.1. Overview 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.8.3. Product Benchmarking 8.4.8.4. Strategic Initiatives 8.4.9. Sysmex Corporation 8.4.9.1. Overview 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.9.3. Product Benchmarking 8.4.9.4. Strategic Initiatives 8.4.10. Agilent Technologies, Inc. 8.4.10.1. Overview 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.10.3. Product Benchmarking 8.4.10.4. Strategic Initiatives 8.4.11. Abbott 8.4.11.1. Overview 8.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.11.3. Product Benchmarking 8.4.11.4. Strategic Initiatives
SummaryAutomated Cell Counting Market Growth & Trends Table of ContentsTable of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation and Scope 1.2. Market Definitions 1.2.1. Product Segment 1.2.2. Application Segment 1.2.3. End-user Segment 1.3. Information analysis 1.4. Market formulation & data visualization 1.5. Data validation & publishing 1.6. Information Procurement 1.6.1. Primary Research 1.7. Information or Data Analysis 1.8. Market Formulation & Validation 1.9. Market Model 1.10. Objectives 1.10.1. Objective 1 1.10.2. Objective 2 Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Snapshot 2.3. Competitive Landscape Snapshot Chapter 3. Market Variables, Trends, & Scope 3.1. Market Lineage Outlook 3.1.1. Parent Market Outlook 3.1.2. Related/Ancillary Market Outlook 3.2. Market Trends and Outlook 3.3. Market Dynamics 3.3.1. Increasing prevalence of chronic diseases 3.3.2. Technological advancements in cell counting instruments 3.3.3. Increasing government funding for cell-based research 3.4. Market Restraint Analysis 3.4.1. High costs of advanced cell counting systems 3.4.2. Low adoption in underdeveloped regions 3.5. Business Environment Analysis 3.5.1. PESTEL Analysis 3.5.2. Porter’s Five Forces Analysis 3.5.3. COVID-19 Impact Analysis Chapter 4. Product Business Analysis 4.1. Global Automated Cell Counting Market: Product Movement Analysis 4.2. Instruments 4.2.1. Instruments Market, 2018 - 2030 (USD Million) 4.2.2. Flow Cytometers 4.2.2.1. Flow Cytometers Market, 2018 - 2030 (USD Million) 4.2.3. Image-based Cell Counters 4.2.3.1. Image-based Cell Counters Market, 2018 - 2030 (USD Million) 4.2.4. Electrical Impendence Coulter Counters 4.2.4.1. Electrical Impendence Coulter Counters Market, 2018 - 2030 (USD Million) 4.3. Consumables & Accessories 4.3.1. Consumables & Accessories Market, 2018 - 2030 (USD Million) Chapter 5. Application Business Analysis 5.1. Global Automated Cell Counting Market: Application Movement Analysis 5.2. Blood Analysis 5.2.1. Blood Analysis Market, 2018 - 2030 (USD Million) 5.3. Stem Cell Research 5.3.1. Stem Cell Research Market, 2018 - 2030 (USD Million) 5.4. Cell Line development 5.4.1. Cell Line development Market, 2018 - 2030 (USD Million) 5.4.2. Biologics Production 5.4.2.1. Biologics Production Market, 2018 - 2030 (USD Million) 5.4.3. Cell & Gene Therapy 5.4.3.1. Cell & Gene Therapy Market, 2018 - 2030 (USD Million) 5.5. Others 5.5.1. Others Market, 2018 - 2030 (USD Million) Chapter 6. End-Use Business Analysis 6.1. Global Automated Cell Counting Market: End-use Movement Analysis 6.2. Pharmaceutical & Biotechnology Companies 6.2.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million) 6.3. Hospitals & Diagnostic laboratories 6.3.1. Hospitals & Diagnostic laboratories Market, 2018 - 2030 (USD Million) 6.4. Research & Academic Institutes 6.4.1. Research & Academic Institutes Market, 2018 - 2030 (USD Million) 6.5. Others 6.5.1. Others Market, 2018 - 2030 (USD Million) Chapter 7. Regional Business Analysis 7.1. Global Automated Cell Counting Market Share By Region, 2023 & 2030 7.2. North America 7.2.1. North America Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.2.2. U.S. 7.2.2.1. Key Country Dynamics 7.2.2.2. Competitive Scenario 7.2.2.3. Target Disease Prevalence 7.2.2.4. U.S. Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.2.3. Canada 7.2.3.1. Key Country Dynamics 7.2.3.2. Competitive Scenario 7.2.3.3. Target Disease Prevalence 7.2.3.4. Canada Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3. Europe 7.3.1. Europe Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3.2. Germany 7.3.2.1. Key Country Dynamics 7.3.2.2. Competitive Scenario 7.3.2.3. Target Disease Prevalence 7.3.2.4. Germany Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3.3. UK 7.3.3.1. Key Country Dynamics 7.3.3.2. Competitive Scenario 7.3.3.3. Target Disease Prevalence 7.3.3.4. UK Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3.4. France 7.3.4.1. Key Country Dynamics 7.3.4.2. Competitive Scenario 7.3.4.3. Target Disease Prevalence 7.3.4.4. France Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3.5. Italy 7.3.5.1. Key Country Dynamics 7.3.5.2. Competitive Scenario 7.3.5.3. Target Disease Prevalence 7.3.5.4. Italy Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3.6. Spain 7.3.6.1. Key Country Dynamics 7.3.6.2. Competitive Scenario 7.3.6.3. Target Disease Prevalence 7.3.6.4. Spain Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3.7. Denmark 7.3.7.1. Key Country Dynamics 7.3.7.2. Competitive Scenario 7.3.7.3. Target Disease Prevalence 7.3.7.4. Denmark Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3.8. Sweden 7.3.8.1. Key Country Dynamics 7.3.8.2. Competitive Scenario 7.3.8.3. Target Disease Prevalence 7.3.8.4. Sweden Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.3.9. Norway 7.3.9.1. Key Country Dynamics 7.3.9.2. Competitive Scenario 7.3.9.3. Target Disease Prevalence 7.3.9.4. Norway Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.4. Asia Pacific 7.4.1. Asia Pacific Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.4.2. Japan 7.4.2.1. Key Country Dynamics 7.4.2.2. Competitive Scenario 7.4.2.3. Target Disease Prevalence 7.4.2.4. Japan Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.4.3. China 7.4.3.1. Key Country Dynamics 7.4.3.2. Competitive Scenario 7.4.3.3. Target Disease Prevalence 7.4.3.4. China Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.4.4. India 7.4.4.1. Key Country Dynamics 7.4.4.2. Competitive Scenario 7.4.4.3. Target Disease Prevalence 7.4.4.4. India Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.4.5. South Korea 7.4.5.1. Key Country Dynamics 7.4.5.2. Competitive Scenario 7.4.5.3. Target Disease Prevalence 7.4.5.4. South Korea Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.4.6. Australia 7.4.6.1. Key Country Dynamics 7.4.6.2. Competitive Scenario 7.4.6.3. Target Disease Prevalence 7.4.6.4. Australia Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.4.7. Thailand 7.4.7.1. Key Country Dynamics 7.4.7.2. Competitive Scenario 7.4.7.3. Target Disease Prevalence 7.4.7.4. Thailand Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.5. Latin America 7.5.1. Latin America Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.5.2. Brazil 7.5.2.1. Key Country Dynamics 7.5.2.2. Competitive Scenario 7.5.2.3. Target Disease Prevalence 7.5.2.4. Brazil Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.5.3. Mexico 7.5.3.1. Key Country Dynamics 7.5.3.2. Competitive Scenario 7.5.3.3. Target Disease Prevalence 7.5.3.4. Mexico Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.5.4. Argentina 7.5.4.1. Key Country Dynamics 7.5.4.2. Competitive Scenario 7.5.4.3. Target Disease Prevalence 7.5.4.4. Argentina Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.6. MEA 7.6.1. MEA Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.6.2. South Africa 7.6.2.1. Key Country Dynamics 7.6.2.2. Competitive Scenario 7.6.2.3. Target Disease Prevalence 7.6.2.4. South Africa Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.6.3. Saudi Arabia 7.6.3.1. Key Country Dynamics 7.6.3.2. Competitive Scenario 7.6.3.3. Target Disease Prevalence 7.6.3.4. Saudi Arabia Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.6.4. UAE 7.6.4.1. Key Country Dynamics 7.6.4.2. Competitive Scenario 7.6.4.3. Target Disease Prevalence 7.6.4.4. UAE Automated Cell Counting Market, 2018 - 2030 (USD Million) 7.6.5. Kuwait 7.6.5.1. Key Country Dynamics 7.6.5.2. Competitive Scenario 7.6.5.3. Target Disease Prevalence 7.6.5.4. Kuwait Automated Cell Counting Market, 2018 - 2030 (USD Million) Chapter 8. Competitive Landscape 8.1. Company Categorization 8.2. Strategy Mapping 8.3. Company Market/Position Share Analysis, 2023 8.4. Company Profiles/Listing 8.4.1. Thermo Fisher Scientific Inc. 8.4.1.1. Overview 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.1.3. Product Benchmarking 8.4.1.4. Strategic Initiatives 8.4.2. Countstar, Inc. 8.4.2.1. Overview 8.4.2.2. Product Benchmarking 8.4.2.3. Strategic Initiatives 8.4.3. Bio-Rad Laboratories, Inc. 8.4.3.1. Overview 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.3.3. Product Benchmarking 8.4.3.4. Strategic Initiatives 8.4.4. F. Hoffmann-La Roche Ltd 8.4.4.1. Overview 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.4.3. Product Benchmarking 8.4.4.4. Strategic Initiatives 8.4.5. Chemometec A/S 8.4.5.1. Overview 8.4.5.2. Product Benchmarking 8.4.5.3. Strategic Initiatives 8.4.6. Danaher 8.4.6.1. Overview 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.6.3. Product Benchmarking 8.4.6.4. Strategic Initiatives 8.4.7. Olympus Corporation 8.4.7.1. Overview 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.7.3. Product Benchmarking 8.4.7.4. Strategic Initiatives 8.4.8. Merck KGaA 8.4.8.1. Overview 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.8.3. Product Benchmarking 8.4.8.4. Strategic Initiatives 8.4.9. Sysmex Corporation 8.4.9.1. Overview 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.9.3. Product Benchmarking 8.4.9.4. Strategic Initiatives 8.4.10. Agilent Technologies, Inc. 8.4.10.1. Overview 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.10.3. Product Benchmarking 8.4.10.4. Strategic Initiatives 8.4.11. Abbott 8.4.11.1. Overview 8.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.11.3. Product Benchmarking 8.4.11.4. Strategic Initiatives
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(バイオ薬物)の最新刊レポート
Grand View Research社の生物分野での最新刊レポート
本レポートと同じKEY WORD(consumables)の最新刊レポート
よくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/21 10:26 156.13 円 165.08 円 200.38 円 |